EUVIMEDEUVIMED entdecken
Crossref

Dextromethorphan inhibits collagen and collagen-like cargo secretion to ameliorate lung fibrosis

Muzamil M Khan iD, George Galea iD, Juan Jung, Joanna Zukowska iD, David Lauer iD, Nadine Tuechler iD, Aliaksandr Halavatyi iD, Christian Tischer iD, Per Haberkant iD, Frank Stein iD, Ferris Jung iD, Jonathan J M Landry iD und 14 weitere

Science Translational Medicine · 2024

DOI: 10.1126/scitranslmed.adj3087 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, 2024. Verfasst von Muzamil M Khan und 25 weiteren Autor:innen. Beteiligte Einrichtung: Cell Biology and Biophysics Unit, European Molecular Biology Laboratory, 69117 Heidelberg, Germany. Hauptthemen laut MEDLINE: Dextromethorphan, Pulmonary Fibrosis, Collagen. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 73 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Excessive deposition of fibrillar collagen in the interstitial extracellular matrix (ECM) of human lung tissue causes fibrosis, which can ultimately lead to organ failure. Despite our understanding of the molecular mechanisms underlying the disease, no cure for pulmonary fibrosis has yet been found. We screened a drug library and found that dextromethorphan (DXM), a cough expectorant, reduced the amount of excess fibrillar collagen deposited in the ECM in cultured primary human lung fibroblasts, a bleomycin mouse model, and a cultured human precision-cut lung slice model of lung fibrosis. The reduced extracellular fibrillar collagen upon DXM treatment was due to reversible trafficking inhibition of collagen type I (COL1) in the endoplasmic reticulum (ER) in TANGO1- and HSP47-positive structures. Mass spectrometric analysis showed that DXM promoted hyperhydroxylation of proline and lysine residues on various collagens (COL1, COL3, COL4, COL5, COL7, and COL12) and latent transforming growth factor–β–binding protein (LTBP1 and LTBP2) peptides, coinciding with their secretion block. Additionally, proteome profiling of DXM-treated cells showed increased thermal stability of prolyl-hydroxylases P3H2, P3H3, P3H4, P4HA1, and P4HA2, suggesting a change in their activity. Transcriptome analysis of profibrotic stimulated primary human lung fibroblasts and human ex vivo lung slices after DXM treatment showed activation of an antifibrotic program through regulation of multiple pathways, including the MMP-ADAMTS axis, WNT signaling, and fibroblast-to-myofibroblast differentiation. Together, these data obtained from in vitro, in vivo, and ex vivo models of lung fibrogenesis show that DXM has the potential to limit fibrosis through inhibition of COL1 membrane trafficking in the ER.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DextromethorphanPulmonary FibrosisCollagenAnimalsHumansBleomycinFibroblastsMiceLungEndoplasmic ReticulumExtracellular MatrixMice, Inbred C57BLCollagen Type IDisease Models, AnimalHydroxylation

Substanzen

DextromethorphanCollagenBleomycinCollagen Type I

Autor:innen und Institutionen

  • Cell Biology and Biophysics Unit, European Molecular Biology Laboratory, 69117 Heidelberg, Germany.
  • Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), 69120 Heidelberg, Germany.
  • Lung Precision Medicine (LPM), Department for BioMedical Research (DBMR), University of Bern, 3008 Bern, Switzerland.
  • Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
  • Department of Pulmonary Medicine, Allergology and Clinical Immunology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
  • Molecular Medicine Partnership Unit, European Molecular Biology Laboratory and Heidelberg University, 69117 Heidelberg, Germany.

ORCID-Profile: Muzamil M Khan, George Galea, Joanna Zukowska, David Lauer, Nadine Tuechler, Aliaksandr Halavatyi, Christian Tischer, Per Haberkant, Frank Stein, Ferris Jung, Jonathan J M Landry, Viola Oorschot, Isabelle Becher, Beate Neumann, Thomas Muley, Hauke Winter, Julia Duerr, Marcus A Mall, Alessandro Grassi, Ernesto de la Cueva, Vladimir Benes, Janine Gote-Schniering, Mikhail Savitski, Rainer Pepperkok

Zitieren

APA

Khan, M. M., Galea, G., Jung, J., Zukowska, J., Lauer, D., Tuechler, N., Halavatyi, A., Tischer, C., Haberkant, P., Stein, F., Jung, F., Landry, J. J. M., Khan, A. M., Oorschot, V., Becher, I., Neumann, B., Muley, T., Winter, H., Duerr, J., …, & Pepperkok, R. (2024). Dextromethorphan inhibits collagen and collagen-like cargo secretion to ameliorate lung fibrosis. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.adj3087

Vancouver

Khan MM, Galea G, Jung J, Zukowska J, Lauer D, Tuechler N, et al. Dextromethorphan inhibits collagen and collagen-like cargo secretion to ameliorate lung fibrosis. Science Translational Medicine. 2024. doi:10.1126/scitranslmed.adj3087

BibTeX
@article{Khan2024,
  author = {Khan, Muzamil M and Galea, George and Jung, Juan and Zukowska, Joanna and Lauer, David and Tuechler, Nadine and Halavatyi, Aliaksandr and Tischer, Christian and Haberkant, Per and Stein, Frank and Jung, Ferris and Landry, Jonathan J M and Khan, Arif M and Oorschot, Viola and Becher, Isabelle and Neumann, Beate and Muley, Thomas and Winter, Hauke and Duerr, Julia and Mall, Marcus A and Grassi, Alessandro and de la Cueva, Ernesto and Benes, Vladimir and Gote-Schniering, Janine and Savitski, Mikhail and Pepperkok, Rainer},
  title = {Dextromethorphan inhibits collagen and collagen-like cargo secretion to ameliorate lung fibrosis},
  journal = {Science Translational Medicine},
  year = {2024},
  doi = {10.1126/scitranslmed.adj3087}
}
Kostenlos starten →